ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group, Nielsen, H & Thisted, R K 2022, ' Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO) : a randomised controlled trial ', The Lancet. Infectious diseases, vol. 22, no. 5, pp. 622-635 . https://doi.org/10.1016/S1473-3099(21)00751-9 ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group, Johansen, I S & Larsen, L 2022, ' Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO) : a randomised controlled trial ', The Lancet Infectious Diseases, vol. 22, no. 5, pp. 622-635 . https://doi.org/10.1016/S1473-3099(21)00751-9 The Lancet. Infectious Diseases
ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group, Nielsen, H, Thisted, R K, Petersen, K T & Juhl, M R 2022, ' Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial ', The Lancet. Respiratory Medicine, vol. 10, no. 10, pp. 972-984 . https://doi.org/10.1016/S2213-2600(22)00215-6